CRTX Summary

  1. NASDAQ
  2. >
  3. CRTX
TickerCRTX
DescriptionCORTEXYME INC
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Employees38
Next Earnings DateNovember 11th, 2021
IV487.891902%
IV Percentile99th
IV Rank99.51%
IV Skew12.940792
IV Skew Percentile82nd
IV Skew SentimentBearish
Option Volume25,462
Volume163,041
Price$58.61
Previous Close$57.00
52-Week High$121.98
52-Week Low$26.6612
50-Day Moving Avg.$86.22
200-Day Moving Avg.$62.81
10-Day Avg. Volume402,508
20-Day Avg. Volume280,585
30-Day Avg. Volume274,078
3-Month Avg. Volume299,156
EPS-$2.94
Outstanding Shares29,685,786
Market Capitalization$1,743,743,100
CurrencyUSD
UpdatedOctober 20th, 2021